Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
1. Original claims 1-6 filed on 12/15/23 are acknowledged and are under consideration in this Office Action.
2. Priority
Receipt is acknowledged of papers (foreign priority filed 12/24/22) submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.
3. Drawings
The drawings filed on 12/15/23 are acknowledged.
4. Specification
The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.
5. Claim Rejections - 35 USC § 112 (second paragraph)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 4 & 6 are drawn to as follows:
4. The recombinant S. cerevisiae according to claim 1 3, wherein pY26 series vectors or pET series vectors are used as expression vectors.
6. A method for synthesizing 3,15,19-Trihydroxy-8(17),13-ent-labdadiene-16-oic acid, using the recombinant S. cerevisiae according to claim 1 or the whole-cell catalyst comprising the recombinant S. cerevisiae as a fermentation strain for fermentation to produce 3,15,19-Trihydroxy-8(17),13-ent-labdadiene-16-oic acid.
Claim 4 recites the limitation " wherein pY26 series vectors or pET series vectors are used as expression vectors" in claim 13. There is insufficient antecedent basis for this limitation in the claim. There is no claim 13 (may be a typo); and further if it were to depend on claim 1 or 3 there is no antecedent basis of the limitation in the claim(s). Rewording/cancellation of the claim is suggested to overcome this rejection.
Claim 6 recites the limitation “or the whole-cell catalyst comprising the recombinant S. cerevisiae as a fermentation strain for fermentation to produce 3,15,19-Trihydroxy-8(17),13-ent-labdadiene-16-oic acid” in claim 1. There is no antecedent basis of the limitation in the claim 1.
Suggestion to split claim 6 into claims 6 & 7 as follows:
6. A method for synthesizing 3,15,19-Trihydroxy-8(17),13-ent-labdadiene-16-oic acid, using the recombinant S. cerevisiae of claim 1, comprising the recombinant S. cerevisiae as a fermentation strain for fermentation to produce 3,15,19-Trihydroxy-8(17),13-ent-labdadiene-16-oic acid.
7. A method for synthesizing 3,15,19-Trihydroxy-8(17),13-ent-labdadiene-16-oic acid, using the whole-cell catalyst of claim 5 comprising the recombinant S. cerevisiae as a fermentation strain for fermentation to produce 3,15,19-Trihydroxy-8(17),13-ent-labdadiene-16-oic acid.
6. claims 1-3 & 5 are allowed.
7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TEKCHAND SAIDHA whose telephone number is (571)272-0940. The examiner can normally be reached on M-F 8.00-5.30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert B Mondesi can be reached on 408 918 7584. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/TEKCHAND SAIDHA/
Primary Examiner, Art Unit 1652
Recombinant Enzymes, Hoteling
Telephone: (571) 272-0940
Fax: (571) 273-0940